UPDATE: Quoin Pharmaceuticals (QNRX) - The Clock Runs Faster Than the Catalysts

The Event. Q2 numbers and a corporate update landed this morning. Cash, equivalents and marketable securities: $10.8M at June 30, 2026, down from $14.0M at March 31. Net loss $5.4M for the quarter, $10.4M for the half. The going-concern paragraph — “substantial doubt about the Company’s ability to continue as a going concern” — is verbatim intact.

The Reaction. The ADSs have run from $3.83 on June 24 to $5.09 — up 32.9% — on a summer of regulatory checkmarks: QYLEKI brand name conditionally accepted, a patent Notice of Allowance, and PSS IND clearance. The equity is re-rating on paperwork, not on efficacy.

The Reality. Burn is accelerating into a smaller bank account, and the single highest-signal event on my board — the unblinding of the only vehicle-controlled study QRX003 has ever run — was not mentioned. Not delayed, not described. Absent.

The Receipts

The balance sheet compressed by $3.2M in 90 days. $3.8M cash + $7.0M investments = $10.8M. Operating cash burn was $8.0M in the first half versus $6.3M in 1H 2025. R&D alone jumped to $3.63M in Q2 from $2.05M a year ago — +76.8% — driven by $1.05M more external clinical spend as sites open in the UK, Spain, France and the Netherlands. Total shareholders’ equity is down to $3.93M from $13.1M at year-end. Why it matters: management again says cash funds operations “into 2027,” but the pivotal Phase 3 hasn’t started spending yet and accounts payable ballooned to $3.1M from $1.26M at December 31. That’s a company stretching its vendors. At a run-rate above $4M/quarter and climbing, the dilution gap I flagged in the deep dive hasn’t narrowed — it’s tightened.

POC 1 is missing from the narrative. The Recent Developments section walks through Saudi Breakthrough filing, Japan ODD, Fast Track, the Type C meeting, the PSS IND, the compassionate-use update, the brand name. The randomized, vehicle-controlled proof-of-concept (CL-QRX003-001, n=13, vehicle vs. 1%/2%/4%) — described in March as “being closed and unblinded” — appears nowhere. Why it matters: I called that unblinding “the most important single event in this entire story,” because it is the first and so far only time this drug gets measured against placebo. Five months of silence on a 13-patient readout is not a neutral data point. It may be a housekeeping non-event, or it may be that the March Type C guidance — where FDA “expressed openness to an alternate study design for Phase 3 that would likely not include a traditional upfront vehicle or placebo control” — made the company comfortable letting a controlled dataset quietly become a footnote. Either way, the thesis still has zero read-out controlled efficacy.

The moat got a patch — a narrow one. On June 30 the USPTO issued a Notice of Allowance for U.S. Patent Application No. 18/428,570, “Combination Treatment for Netherton Syndrome” — method claims covering a topical serine protease inhibitor used together with an anti-inflammatory agent, including in SPINK5-mutant patients. Why it matters: in the deep dive I called the licensed-and-amortizing Skinvisible position the soft underbelly of this story — a delivery patent being written down to near-zero by 2029 with no disclosed composition-of-matter claim of Quoin’s own. This is the first IP Quoin appears to hold in its own name. But read the claim carefully: it’s a method-of-use patent on a combination, not composition-of-matter on the active. Method claims are the weakest tier of pharmaceutical IP — they’re routinely designed around by label carve-outs, and they don’t stop a competitor from selling the same molecule for a different regimen. It thickens the fence; it doesn’t build a wall. The real moat here remains 7 years of US orphan exclusivity on first approval.

PSS got upgraded from Phase 2 to Phase 2/3. FDA cleared the first-ever Peeling Skin Syndrome IND on July 9, 2026, with “no safety concerns regarding study design or duration of dosing,” and the study is now described as a Phase 2/3 enrolling pediatric and adult patients in the US and Europe, initiating 2H 2026. Why it matters: a 2/3 label means the study is being built to potentially support registration rather than just generate signal — meaningful for a second indication on the same molecule in another disease with no approved therapy. It also means it costs more. This is real optionality and a real cash draw arriving simultaneously.

Compassionate use expanded to eight patients, with three more expected. The 10-Q updates the pediatric program from six to eight patients dosing across Ireland, Austria, the Netherlands and New Zealand. Why it matters: the June update reported 4 of 6 “improved” or “significantly improved” with no treatment-related adverse events. Growing that denominator is genuinely useful — but it remains open-label, baseline-controlled, single-arm data in the youngest and most severely affected patients. Impressive as a set of anecdotes. Not evidence in the regulatory sense.

The Scientific Reality Check

Here’s the honest read on what nine months of designations have and haven’t done.

Read more